23.5 C
New York
Thursday, July 3, 2025

Tag: disease control

newssourcecompanyFORcontentinformation1marketbusiness

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study

Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation...

Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H)...

Strobilurin Market worth $6.88 billion by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 2, 2025 /PRNewswire/ -- The strobilurin market is projected to expand from USD 5.53 billion in 2025 to USD 6.88...

Strobilurin Market worth $6.88 billion by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., July 2, 2025 /PRNewswire/ -- The strobilurin market is projected to expand from USD 5.53 billion in 2025 to USD 6.88...

HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach

TAIPEI and SHANGHAI and SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology...

Zynex Announces Award of UK Patent for Non-Invasive Detection of Sepsis

ENGLEWOOD, Colo., June 25, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices...

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

Health and Wellness Market Size Worth USD 11 Trillion by 2034

The health and wellness market size is expected to be worth over USD 11 trillion by 2034, increasing from USD 6.57 trillion in 2024, with a CAGR of 5.50%. The market of health and wellness is driven by rising health awareness, an aging population, technological advancements, growing health consciousness, and supportive government initiatives. 
The health and wellness market size is expected to be worth over USD 11 trillion by 2034, increasing from USD 6.57 trillion in 2024, with a CAGR of 5.50%. The market of health and wellness is driven by rising health awareness, an aging population, technological advancements, growing health consciousness, and supportive government initiatives.

Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing

Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient...

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDisease control

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers